Cystinuria type I: Identification of eight new mutations in SLC3A1  by Bisceglia, Luigi et al.
Kidney International, Vol. 59 (2001), pp. 1250–1256
Cystinuria type I: Identification of eight new mutations
in SLC3A1
LUIGI BISCEGLIA,1 JESU´S PURROY,1 MAITE JIME´NEZ-VIDAL, ADAMO P. D’ADAMO,
FERRAN ROUSAUD, ERCOLE BECCIA, ROSA PENZA, GIANFRANCO RIZZONI, MICHELE GALLUCCI,
MANUEL PALACI´N, PAOLO GASPARINI, VIRGINIA NUNES, and LEOPOLDO ZELANTE
Servizio di Genetica Medica, IRCCS-Ospedale “Casa Sollievo della Sofferenza” San Giovanni Rotondo (Foggia), Italy;
Departament de Gene`tica Molecular, Institut de Recerca Oncolo`gica, L’Hospitalet de Llobregat, Departament de Bioquı´mica i
Fisiologia, Facultat de Biologia, Universitat de Barcelona, and Servicio de Nefrologia IUNA, Fundacı`on Puigvert, Barcelona,
Spain; and Divisione di Urologia, IRCCS-Ospedale “Casa Sollievo della Sofferenza” San Giovanni Rotondo, Dipartimento di
Biomedicina dell’Eta` Evolutiva, Universita` di Bari, Divisione di Nefrologia e Dialisi, Ospedale Pediatrico “Bambino Gesu”-
IRCCS, and Divisione di Urologia, Ospedale “Cristo Re,” Roma, Italy
Cystinuria type I: Identification of eight new mutations in Cystinuria (MIM 220100) is the most common herita-
SLC3A1. ble disorder of amino acid transport, and is transmitted
Background. Cystinuria is a heritable disorder of amino acid as an autosomal recessive trait with an overall prevalencetransport characterized by the defective transport of cystine
of 1 in 7000 [1]. The disease is characterized by a nephronand the dibasic amino acids through the brush border epithelial
and intestinal defect in the reabsorption of cystine andcells of the renal tubule and intestine tract. Three types of
cystinuria (I, II, and III) have been described based on the the dibasic amino acids, arginine, lysine, and ornithine
urinary excretion of cystine and dibasic amino acids in obligate through the brush border epithelial cells of the renal
heterozygotes. The SLC3A1 gene coding for an amino acid tubule and intestinal tract [2]. Because of the low solubil-
transporter named rBAT is responsible for type I cystinuria,
ity of cystine in urine, the increased urinary excretionwhereas the SLC7A9 gene coding for a subunit (b0,1AT) of
results in the formation of cystine stones that representrBAT is involved in determining non-type I (types II and III)
cystinuria. 1 to 2% of all urinary lithiasis.
Methods. The SLC3A1 gene sequence was investigated in a Three types of classic cystinuria (I, II, and III) have
sample of seven type I/type I, three type I/non-type I, six type been described based on the urinary excretion of cystine
I/untyped, and four untyped unrelated cystinuric patients by and dibasic amino acids in obligate heterozygotes [3]RNA single-strand conformation polymorphism (RNA-SSCP).
and on intestinal absorption in homozygotes [1]. Type IResults. Eight new point mutations (S168X, 76511G.T,
heterozygotes show normal aminoaciduria, whereas type II766-2A.G, R452Q, Y461X, S547W, L564F, and C673W) and
seven previously reported mutations were detected. These new and III heterozygotes show high or moderate hyper-
mutations increase the number of mutated alleles so far charac- excretion of cystine and dibasic amino acids. Type I and
terized in SLC3A1 to 62. II homozygotes show a minimal increase in blood cystine
Conclusions. We have found SLC3A1 mutations in 0.739 of
levels after oral loading, whereas type III homozygotesthe type I chromosomes studied. The relatively high proportion
exhibit a near normal response. Despite these differ-of uncharacterized type I chromosomes suggests either that
there may be mutations not yet found in SLC3A1 or that many ences, the distinction between types II and III is very un-
of the assigned type I chromosomes in mixed type I/non-type I clear. Therefore, we distinguish two clinical types: (a)
patients may have mutations in SLC7A9. If the hypothesis is type I heterozygotes, which present normal aminoacid-
excluded in the future, we believe that a third gene may be in- uria, and (b) non-type I heterozygotes, which show a vari-volved in cystinuria.
able degree of urinary hyperexcretion of cystine and
dibasic amino acids [4]. In addition, our linkage data
1 Dr. Bisceglia and Dr. Purroy contributed equally to this work. emphasize the hypothesis that types II and III must be
considered together [5].Key words: SLC3A1 gene mutation, SLC7A9 gene mutation, chromo-
somes, rBAT mutation, inheritance, urinary cystine, amino acid trans- All pathological consequences of cystinuria are related
port, nephron defect, urolithiasis. to urolithiasis, that is, urinary tract infection, pyelo-
nephritis, obstructive uropathy, and renal insufficiency.Received for publication January 24, 2000
The intestinal defect in the absorption of cystine andand in revised form October 31, 2000
Accepted for publication November 6, 2000 dibasic amino acids does not have any practical conse-
quences.Ó 2001 by the International Society of Nephrology
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Table 1. Urine amino acid levels in SLC3A1 obligate heterozygotes and controls
Cys Lys Arg Orn Sum
Obligate heterozygotes (N 5 22) 79613 146619 1864 4169 282634
Maximum–minimum values 20–241 28–333 0–88 5–163 69–567
5–95 percentile (25–159) (40–311) (0–40) (10–144) (105–484)
Controls (N 5 34) 4063 118610 1866 2164 197618
Maximum–minimum values 15–70 23–311 0–171 0–97 71–635
5–95 percentile (18–61) (50–227) (0–72) (1–72) (94–350)
Urinary excretion of cystine, lysine, arginine and ornithine, and the sum of these four amino acids in obligate heterozygotes of type I cystinuria families and in
controls, expressed in mmol/g of creatinine. Controls are relatives of cystinuria patients with no identified mutations in SLC3A1 or SLC7A9, and non-transmitting
cystinuria. These heterozygotes and controls were identified prior to the present study. Data (mean 6 SEM) are expressed in mmol/g of creatinine in 24-hour urine
samples. The 5–95 percentile of each value is given in parenthesis. ‘N’ denotes the number of individuals.
In 1994, the cystinuria type I gene (SLC3A1) was identi- and ornithine (Table 1). When at least two parameters
(cystine, lysine, or the sum of cystine and dibasic aminofied [6]. In 1997, non-type I cystinuria (types II and III)
was linked to a locus on 19q13 [5, 7]. In 1999, SLC7A9, acids) were higher than the maximum value of heterozy-
gotes for mutations in SLC3A1, the proband’s relativesthe gene causing non-type I cystinuria, was identified [4].
To date 54 mutations (44 point mutations, 9 large de- were classified as non-type I heterozygotes. Otherwise,
they were classified as type I heterozygotes. Seven pa-letions, and 1 complex mutation) have been described
[6, 8–21]. (abstract; Boutros et al, Am J Hum Genet tients were classified as type I/type I, three as mixed type
I/non-type I, and six as type I/untyped. A summary of65:491, 1999) in the SCC3A1 sequence.
This study describes eight new mutations resulting the phenotypes of patients included in this study is re-
ported in Table 2. We do not have any information aboutfrom a mutational search on a series of seven type I/type I,
the stone formation in the patients D3 and B96; all thethree type I/non-type I, six type I/untyped, and four
remaining but two formed stones in the first one thirduntyped patients obtained analyzing the whole SLC3A1
decade of life. In addition, the patients P.G., IM93, andcoding region, intron/exon boundaries, and 323 nucleo-
PR84 underwent the nephrotomy, whereas patient B48tides of promoter sequence directly on genomic DNA.
had a cystinuric brother affected by renal failure. WhenThe methods of choice were the RNA single-strand con-
24-hour urine samples of the proband’s parents were notformation polymorphism (RNA-SSCP) technique [22, 23].
available, we considered urine samples of the pro-Previous data on the frequency of 21 different muta-
band’s children. Urinary amino acid content measure-tions in our population indicated that approximately
ments, determined by high-pressure liquid chromatogra-0.574 of the overall type I chromosomes were character-
phy (HPLC), were corrected per gram of creatinine.ized by mutations in SLC3A1 [11]. In the current study,
we report the characterization of 17 out of 23 type I
Mutational searchchromosomes that account for a proportion of 0.739, and
Genomic DNA was isolated from peripheral bloodalso describe the overall number of SLC3A1 mutations
lymphocytes according to standard protocols. DNA am-detected so far in our cystinuric population.
plification by polymerase chain reaction (PCR) was car-
ried out incorporating the T7 phage promoter sequence
METHODS
in the 59-end of one PCR primer. In this manner, the
Patients amplified product can be processed by the RNA-SSCP
technique [22, 23]. The primer pairs and the PCR proto-Twenty unrelated Italian and Spanish patients were
analyzed. Sixteen of them were classified in cystinuria col conditions used to amplify the SLC3A1 exons were
those previously described [11].subtypes on the basis of urinary excretion values of cys-
tine and dibasic amino acids in 24-hour urine specimens The promoter region was amplified using the primer
pairs Dir/59-CTGGGATTACAGGTGCACAC-39 (2343;of their relatives. Four patients who were included in
this study remained unclassified because of the impossi- 2324) and Rev/59-TATCTTCAGCCATGTCTCAC-39
(13; 27) under the following conditions: 958C for 5 min-bility to recruit their relatives or because the urine analy-
sis was not exhaustive. The criteria for classification were utes, followed by 35 cycles at 948C for 30 seconds, 578C
for 30 seconds, and 728C for 30 seconds. To the 59-endbased on the excretion levels of known heterozygotes
for mutations in SLC3A1 (Table 1). It is worth men- of the forward primer was added a T7 tail, as described
previously in this article. The amplification reaction wastioning that the range of the urinary excretion of cystine
and the three dibasic amino acids in these SLC3A1 het- performed using 100 ng of genomic DNA in a total volume
of 225 mL, with 5 pmol of each primer and 200 mmol/Lerozygotes was similar to that of controls, but had a
tendency for a higher range in the urine levels of cystine of each dNTP, in PCR buffer containing 1.5 mmol/L
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MgCl2 (final concentration) and 0.7 U of Taq polymerase
(Boehringer Mannheim, Mannheim, Germany).
The RNA-SSCP protocol has been performed as pre-
viously described [9]. Bands showing an electrophoreti-
cally altered mobility were then sequenced on a DNA
Automatic Sequencer (Applied Biosystems 373A) using
the ABI PRISM Dye primer Cycle Sequencing kit ac-
cording to manufacturer’s protocols.
New mutations were also checked by restriction analy-
sis with the enzymes TaqI, MspI, MboI (Promega, Madi-
son, WI, USA), HincII, NcoI (New England BioLabs Inc.,
Boston, MA, USA), AluI, MaeI, and RsaI (Boehringer
Mannheim GmbH), according to manufacturer’s instruc-
tions. Whenever necessary, a modified primer was de-
signed to construct a restriction site during the PCR
(Table 3).
RESULTS
The whole SLC3A1 coding region, all intron/exon boun-
daries, some intron sequences (on average 50 bp on each
side of the exons), and 323 bp of promoter region were
investigated in a sample of 20 Italian and Spanish cysti-
nuric patients. Eight novel mutations were identified:
four missense mutations, two nonsense mutations, and
two involving a splicing site. We also detected seven pre-
viously reported mutations. A summary of the SLC3A1
mutations identified in each cystinuria family is reported
in Table 2, and the novel mutations are listed in Table 3.
Description of new mutations
Missense mutations. A C to G substitution at nucleo-
tide position 2019 of the gene (exon 10), which changed a
cysteine codon (TGC) to a tryptophan (TGG) at position
673 (C673 W), was found in a type I/type I Spanish patient
carrying on the other chromosome the 766-2A.G muta-
tion (discussed later in this article). The C673W mutation
could be detected by the restriction site generating-poly-
merase chain reaction (RG-PCR) method by creating a
NcoI restriction site.
The second mutation was a G to A substitution at nu-
cleotide position 1355 (exon 8). The normal codon (CGG),
corresponding to arginine residue at position 452, changed
to a CAG glutamine codon (R452Q). It was found in one
Italian affected chromosome. The mutation could be
analyzed by PCR since it created an AluI restriction site.
The third identified mutation was a C to G substitution
at nucleotide position 1640 (exon 10). It changes a ser-
ine codon (TCG) to a tryptophan (TGG) at position 547
(S547W). It was found in one Italian affected chromo-
some. Since this substitution created a MboI restriction
site, restriction digestion of the PCR fragment was used
to confirm the sequence change in the patient.
The fourth mutation identified was a C to T substitu-
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tion at nucleotide position 1690 (exon 10) that changed a
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leucine codon (CTC) to a phenylalanine (TTC) at position origin [11]. Also, the mutation M467K described before
in an Italian patient from Southern Italy [6] in our study564 (L564F). It was found in one Italian patient carrying
another chromosome, the M467T mutation. The muta- was detected in a patient from the same geographic area.
A Northern Italian patient was found to carry the muta-tion could be analyzed by RG-PCR protocol by destroy-
ing a RsaI restriction site. tion R452W previously described in one American pa-
tient [13]. A Spanish patient has been found to carryAll missense mutations identified affected residues that
were highly conserved in rat, rabbit, and humans [24–26]. the mutation R365W previously reported in an Italian
patient [9]. Altogether, six subjects were found to beNonsense mutations. A C to A substitution at nucleotide
503 (exon 2) was detected in one Spanish-affected chro- heterozygous for the M467T mutation.
A summary of all mutations identified is reported inmosome. This point mutation led to a stop signal (TAG)
at position 168 (S168X), and it could be analyzed by the Table 2.
RG-PCR protocol since it destroys a TaqI restriction
Survey of the frequency and the occurrence ofsite. Moreover, subject B78 appeared to be homozygous
mutations in our cystinuric populationfor the observed mutation S168X (data not shown), but
further analysis of his relatives allowed us to confirm his In this study, we identified both mutated alleles in four
out of seven type I/type I patients, in three out of sixhemizygous status. The characterization of this deletion
is in progress. type I/untyped patients, and in two out of four untyped
patients; one mutated allele in two out of seven typeThe second mutation was a T to G substitution at nu-
cleotide position 1383 (exon 8) that changed a TAT to a I/type I patients, in three out of six type I/untyped pa-
tients, in one out of three type I/non-type I patients, andTAG codon, resulting in a nonsense mutation at position
461 (Y461X). It was found in one Italian patient carrying in one out of four untyped patients. Thus, we have char-
acterized 25 out of 40 total chromosomes for SLC3A1on the other chromosome, the M467T mutation. The
mutation could be analyzed by the RG-PCR protocol mutations. Ten out of 14 positive chromosomes were
by creating a MaeI restriction site. found in type I/type I patients accounting for a propor-
Splicing site mutation. A G to T substitution at nucleo- tion of 0.714, 1 out of 6 in type I/non-type I patients, 9
tide 76511 (splice site exon 3/intron 3) was found in two out of 12 in type I/untyped, and 5 out of 8 in untyped
Spanish patients. One of them was heterozygous, and patients. If we consider all of the type I chromosomes
the other one was homozygous for this point mutation; from type I/I, type I/non-type I, and type I/untyped pa-
it was possible to confirm the heterozygous state in his tients (17 out of 23), this figure is 0.739. In our cystinuric
parents. The substitution destroyed the consensus se- population, mutation M467T is the most common allele,
quence of splicing site and could be analyzed by the while mutations 163delC, T216M, 7651 1G.T, R362C,
RG-PCR method by creating a HincII restriction site. R365W, M467K, and E483X were detected at least twice
An A to G substitution at nucleotide 766-2 (splice site (Table 4) [6, 9, 11, 12, 16].
intron 3/exon 4) was found in a Spanish patient who
carried the C673W mutation on the other chromosome.
DISCUSSIONThe substitution destroyed the consensus site of splicing
In this study of 20 cystinuric patients, seven patientssite and could be analyzed by PCR since it created a
were classified as type I/type I, three as mixed type I/non-MspI restriction site.
type I, and six as type I/untyped; four patients remainedNone of the described mutations were detected on 86
unclassified because of the impossibility to recruit theirnormal control chromosomes. A summary of the eight
relatives or because the urine analysis was not exhaus-mutations and primers for the PCR amplification is in
tive. The levels of cystine excretion in our patients rangedTable 3.
from 588 to 5689 mmol/g creatinine, and the sum of
Previously reported mutations cystine and dibasic amino acids ranged from 2135 to
30250 mmol/g creatinine. Five patients formed stones atIn addition to the identification of new alleles, we have
age one to five years. Eleven formed stones in the seconddetected seven previously described mutations that char-
to third decade of life, whereas the patients B48 andacterize 14 chromosomes in our sample. A Spanish pa-
DGV103, 43 and 7 years old, respectively, did not formtient was found to be homozygous for the mutation
stones. The cystinuria in these patients was diagnosed163delC [16], and it was possible to confirm the heterozy-
because B48 had a cystinuric brother affected by renalgous state in his parents. A patient of Balkan origin was
failure and DGV103 had recurrent episodes of micro-found to be homozygous for a T216M mutation first
ematuria. In addition, the patients P.G., IM93, and PR84reported in homozygosity in an Italian gypsy [11] and
underwent the nephrotomy. No information about thevery frequently appearing in Greek patients [18]. A pa-
stone formation in patients D3 and B96 was available.tient from Southern Italy was found to carry the mutation
R362C, previously reported in an individual of the same The mutational analysis carried out in this group of pa-
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Table 4. SLC3A1 mutations detected in our cystinuric population tients allowed us to identify eight novel SLC3A1 muta-
tions that together with the 54 previously reported in-Number of
Mutation positive alleles Reference crease to 62 (63 if we consider the large deletion of B78
M467T 22 [6] patient under characterization) the number of different
T216M 4 [11] mutated alleles identified so far in the SLC3A1 gene.
76511G.T 3 this study
Among these new mutations, two are nonsense (S168X,R365W 2 [9]
163delC 2 [16] Y461X) leading to a truncated protein, two involve a
R362C 2 [11] splicing site (76511G.T, 766-2A.G), and the re-
M467K 2 [6]
maining four are missense mutations (R452Q, S547W,E483X 2 [12]
Y151N 1 [11] L564F, C673W) that affect residues highly conserved in
S168X 1 this study rat, rabbit, and human rBAT [24–26].
R181Q 1 [6]
Comparing our data with those arising from otherR270X 1 [8]
R452W 1 [13] populations [8, 10, 12–18, 20–21], the mutation M467T
R452Q 1 this study is the most common allele, and 10 out of 62 mutated
Y461X 1 this study
alleles (163delC, T216M, 765 1 1G.T, R270X, R362C,S547W 1 this study
L564F 1 this study R365W, R452W, M467T, M467K, and E483X) were de-
Y582H 1 [9] tected more than once. This finding combined with the
P615T 1 [6]
evidence of identification of the same mutations in indi-F648S 1 [9]
T652R 1 [6] viduals from identical geographic areas suggests that the
C673W 1 this study majority of the mutations in SLC3A1 should be private
L678P 1 [6]
mutations or/and population specific.766-2A.G 1 this study
1749delA 1 [9] In our study, the overall proportion of type I chromo-
766-2055 del (ex 4–10) 1 [11] somes analyzed in this cystinuric population that were
del (ex 2–10) 1 [19]
positive for point mutations in the SLC3A1 gene is 0.739.del (ex 10) 1 [19]
G(2265)A 0 absa The remaining uncharacterized chromosomes may be
G(2194)C 0 absa explained partially by some mutations escaping detec-
P122S 0 [21]
tion by the RNA-SSCP method or by the presence ofP128Q 0 [8]
S217R 0 [15] mutations in the 59-UTR region beyond the 323 bases
E268K 0 [10] analyzed in this study. The data available concerning the
R270L 0 [15]
promoter of SLC3A1 are not sufficient to determine anyT341A 0 [10]
L346P 0 [20] regions particularly susceptible of carrying mutations in
R365L 0 [18] cystinuria patients. The proportion of type I-positive
S420C 0 [16]
chromosomes in the present study (0.739) is higher asI445T 0 [20]
G458E 0 [16] compared with that reported in our previous studies.
Y461H 0 [13] This finding is probably due to the more stringent criteria
V536G 0 [16]
for classification that is currently used, which now al-G645A 0 [16]
C673R 0 [20] lowed us to classify as non-type I some patients pre-
89114 A.G 0 [17] viously considered in a different way, and to exclude
782–804del 0 [16]
some still biochemically unclassified cases. In addition,974delGA 0 [12]
1011G.A 0 [15] there is evidence that in some patients the type I cystinu-
1306insG 0 [8] ria can be due to mutations in SLC7A9, the gene involved
150011 G.T 0 [12]
in determining non-type I cystinuria. Actually, the Span-1601delAC 0 [21]
1810delTG 0 [15] ish patient B.E., classified as mixed type I/non-type I,
1820delT 0 [20] did not present any mutation in SLC3A1 (Table 2), while
1898insTA 0 [20]
he carried the A182T mutation in SLC7A9 [4] segregat-2022insT 0 [16]
114–1306 del (ex 1–7) 0 [8] ing with the type I phenotype of his father (data not
198–1575 del (ex 1–9) 0 [12] shown). This evidence opens the possibility that other
430–765 del (ex 1–3) 0 [14]
patients phenotypically characterized as mixed typedel (ex 2–10) 0 [15]
del (ex 1–7) 0 [15] I/non-type I may have one particular point mutation in
431-3C to 463T del and SLC7A9 producing a type I cystinuria phenotype. This
duplication ins T468-A474 0 [16]
would explain why in some populations the detectionTotal 59
rate is very high among type I/type I patients (0.94),a The abstract that describes this mutation is Boutros et al, Am J Hum Genet
65:491, 1999 while it is only 0.11 in mixed type I/non-type I patients
[15]. At this point, it would be useful to screen for
SLC7A9 mutations in all patients with type I cystinuria
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amino acid transporter gene associated with cystinuria. Biochemphenotype who have no SLC3A1 mutations. Finally, we
J 310:951–955, 1995
cannot exclude an additional, as yet unidentified gene 11. Bisceglia L, Calonge MJ, Dello Strogolo L, et al: Molecular
analysis of the cystinuria disease gene: Identification of four newto be involved in cystinuria.
mutations, one large deletion, and one polymorphism. Hum Genet
98:447–451, 1996
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